Washburn Capital Management Inc. Acquires Shares of 1,898 Eli Lilly and Company (NYSE:LLY)

Washburn Capital Management Inc. acquired a new stake in Eli Lilly and Company (NYSE:LLYGet Rating) during the 2nd quarter, Holdings Channel reports. The institutional investor acquired 1,898 shares of the company’s stock, valued at approximately $615,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Cordant Inc. acquired a new position in shares of Eli Lilly and in the first quarter valued at approximately $25,000. Icapital Wealth LLC acquired a new position in shares of Eli Lilly and in the first quarter valued at approximately $28,000. HWG Holdings LP acquired a new position in shares of Eli Lilly and in the fourth quarter valued at approximately $28,000. Oliver Lagore Vanvalin Investment Group acquired a new position in shares of Eli Lilly and in the first quarter valued at approximately $33,000. Finally, Selective Wealth Management Inc. acquired a new stake in Eli Lilly and during the first quarter worth approximately $33,000. Institutional investors own 82.45% of the company’s stock.

Eli Lilly and Stock Up 0.1 %

Shares of LLY traded up $0.21 during trading hours on Friday, hitting $311.08. The stock had a trading volume of 101,703 shares, compared to its average volume of 2,237,822. The firm has a market capitalization of $295.58 billion, a P/E ratio of 49.58, a price-to-earnings-growth ratio of 1.92 and a beta of 0.38. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.10 and a quick ratio of 0.85. Eli Lilly and Company has a 1-year low of $220.20 and a 1-year high of $335.33. The firm has a 50 day simple moving average of $314.33 and a 200-day simple moving average of $304.45.

Eli Lilly and (NYSE:LLYGet Rating) last released its quarterly earnings results on Thursday, August 4th. The company reported $1.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.86 by ($0.61). The company had revenue of $6.49 billion for the quarter, compared to analyst estimates of $6.85 billion. Eli Lilly and had a net margin of 19.58% and a return on equity of 85.58%. Eli Lilly and’s revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter last year, the firm posted $1.87 EPS. Sell-side analysts predict that Eli Lilly and Company will post 7.97 EPS for the current fiscal year.

Eli Lilly and Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 9th. Shareholders of record on Monday, August 15th were paid a dividend of $0.98 per share. The ex-dividend date of this dividend was Friday, August 12th. This represents a $3.92 dividend on an annualized basis and a yield of 1.26%. Eli Lilly and’s dividend payout ratio (DPR) is currently 62.52%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on LLY. StockNews.com raised Eli Lilly and from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 14th. BMO Capital Markets increased their price target on Eli Lilly and from $369.00 to $396.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 6th. Citigroup increased their price target on Eli Lilly and from $285.00 to $370.00 in a research report on Thursday, August 25th. Barclays increased their price target on Eli Lilly and from $333.00 to $355.00 and gave the stock an “overweight” rating in a research report on Thursday, July 7th. Finally, JPMorgan Chase & Co. increased their price target on Eli Lilly and from $340.00 to $355.00 in a research report on Wednesday, June 1st. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and presently has an average rating of “Moderate Buy” and an average price target of $332.19.

Insider Buying and Selling at Eli Lilly and

In related news, Director Jackson P. Tai purchased 656 shares of the business’s stock in a transaction on Friday, August 12th. The stock was acquired at an average price of $304.19 per share, for a total transaction of $199,548.64. Following the purchase, the director now owns 62,857 shares of the company’s stock, valued at $19,120,470.83. The transaction was disclosed in a filing with the SEC, which is available at this link. In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 89,458 shares of Eli Lilly and stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $332.85, for a total transaction of $29,776,095.30. Following the transaction, the insider now owns 103,875,441 shares of the company’s stock, valued at approximately $34,574,940,536.85. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jackson P. Tai bought 656 shares of the company’s stock in a transaction on Friday, August 12th. The shares were purchased at an average cost of $304.19 per share, for a total transaction of $199,548.64. Following the transaction, the director now owns 62,857 shares in the company, valued at $19,120,470.83. The disclosure for this purchase can be found here. In the last quarter, insiders sold 328,125 shares of company stock worth $108,581,151. Insiders own 0.12% of the company’s stock.

Eli Lilly and Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Read More

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.